UBS Upgrades Alnylam Pharmaceuticals (ALNY) to Buy, 'Achievable 5-year CAGR goal'

October 4, 2021 7:04 AM EDT
Get Alerts ALNY Hot Sheet
Price: $208.56 -0.35%

Rating Summary:
    19 Buy, 12 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 13 | Down: 13 | New: 72
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

UBS analyst Esther Rajavelu upgraded Alnylam Pharmaceuticals (NASDAQ: ALNY) from Neutral to Buy with a price target of $215.00 (from $141.00).

The analyst comments "ALNY offers a proven platform technology with multiple marketed products in early stages of growth and a strong pipeline of clinical stage assets. Importantly, over the next 12-24 months, we expect continued uptake in revenues and meaningful value
inflections tied to the pipeline including likely approval of Vutrisiran in ATTR-PN, Leqvio (partnered) in dyslipidemia, Onpattro Phase 3 data in ATTR-CM, and Zilebesiran Phase 2 data in hypertension. Most importantly we believe ALNY is well positioned for commercial execution and may likely exceed 5-year revenue CAGR of 40%. While some of this growth potential is reflected at current trading levels, we believe there is room for incremental value creation both with commercial momentum as well as pipeline progress. We estimate ALNY revenues should grow at a 5-year CAGR of ~46% ('20A-'25E), primarily tied to growth in the ATTR franchise with incremental contribution from Givlaari and Oxlumo."

For an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.

Shares of Alnylam Pharmaceuticals closed at $192.68 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, Hot Comments, Hot Upgrades, Upgrades

Related Entities